TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01743261

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: multidisciplinary intervention
Description: Multidisciplinary intervention Instruments of governance are the diagnostic-therapeutic rehabilitation pathways (DTRP), the Quality system and product standards; Medical care process with result-oriented autonomy Technology support of vital signs.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: specific pathology. access is determined by clinical stability. the instruments of governance are guidelines and consensus and the rehabilitation programme is focused on functional and cognitive areas.~the medical care process is governed by hierarchy. The technology in this model is limited to a specific specialty
Study: NCT02575807

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: via IV infusion
Study: NCT00956410

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAD106
Study: NCT03407326

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alternative RUTF
Description: The alternative RUTF contains oat, peanuts, sugar, milk powder, vegetable oil as well as premix containing concentrated minerals and vitamins and emulsifier.
Study: NCT01753570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFN beta(24 weeks)
Description: IFN beta: 600 MIU/day,6 days/week for initial 4 weeks following to 3 days/week for 24 weeks
Study: NCT03392220

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral Neck Dissection
Description: patient undergo bilateral neck dissection, along with the excision of the laryngeal primary tumor
Study: NCT01926834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erigeron Injection
Description: Erigeron Injection, 30ml, iv, qd, for 7days
Study: NCT01753570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV(48 weeks)
Description: RBV: 600 - 1000mg/day based on body weight for 48 weeks
Study: NCT03407326

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard RUTF
Description: Standard RUTF contains peanut paste, sugar, non-fat dried milk (NFDM), vegetable oil, a premix containing concentrated minerals and vitamins, and emulsifier.
Study: NCT00403273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A
Description: 100 units of Botulinum toxin A in 5 cc of normal saline in the Painful TKA at screening visit

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Single Intra-articular Injection of 5 cc of normal saline in the Painful TKA at screening visit
Study: NCT00437294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzastaurin
Description: 1125 milligrams (mg) loading dose then 500 mg, oral, daily, 21-day cycles until progressive disease

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral, daily, 21-day cycles until progressive disease

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: 1250 mg/m\^2, BID, days 1-14 of each 21-day cycle until progressive disease

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: capecitabine
Description: 1250 mg/m\^2, BID, days 1-14 of each 21-day cycle until progressive disease
Study: NCT01541644

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Participants will receive acupuncture treatment twice weekly for 2 weeks, then once per week for 4 weeks, and then biweekly for 4 weeks.
Study: NCT02491086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy (NRT) sampling
Description: 1-week free NRT

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking cessation counseling
Description: Smoking cessation counseling
Study: NCT04124172

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Real rTMS (Magstim)
Description: See arm description

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: See arm description
Study: NCT02266056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular block using rocuronium and reversal with suggamadex
Description: Deep neuromuscular block and moderate neuromuscular block with Esmerone and reversal with bridion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moderate neuromuscular block using rocuronium and reversal with suggamadex
Description: Moderate neuromuscular block and moderate neuromuscular block with Esmerone and reversal with bridion
Study: NCT02110992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 15mg/m2 IV, given days 1, 8, and 15 during SBRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiation
Description: SBRT will be given over 5 fractions separated by \> 48 hours. Dose will be determined based upon dose escalation schedule and will range from 25-40 Gy.
Study: NCT02145039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 30 mg/m2 IV over 30-60 minutes on days -6 through -2 before transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 14.5 mg/kg IV over 1-2 hours on days -6 and -5 before transplant and Cyclophosphamide 50 mg/kg IV on days 3 and 4 post-transplant.
Study: NCT02491086

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking cessation counseling
Description: Smoking cessation counseling
Study: NCT01905891

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Superficial shave biopsy
Description: Sample will be obtained from random dorsal forearm skin sites without evidence of keratotic lesions. The site will be selected by the investigator. Skin will first be wiped with an alcohol pad and 1% lidocaine will be superficially infiltrated per standard skin surgical procedures. 30% trichloroacetic acid (TCA, standard chemical peel) will then be applied for five minutes. TCA will be neutralized using bicarbonate. Using a cytology brush (a small brush which is used to collect cells during the course of a biopsy) cells will be collected by gentle scraping surface of the skin. Then, a superficial shave biopsy specimen, obtained by using a dermablade (a flexible, one piece blade specifically designed for shave biopsy and excision of skin lesions) will be obtained.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Superficial shave biopsy
Description: Sample will be obtained from random dorsal forearm skin sites without evidence of keratotic lesions. The site will be selected by the investigator. Skin will first be wiped with an alcohol pad and 1% lidocaine will be superficially infiltrated per standard skin surgical procedures. 30% trichloroacetic acid (TCA, standard chemical peel) will then be applied for five minutes. TCA will be neutralized using bicarbonate. Using a cytology brush (a small brush which is used to collect cells during the course of a biopsy) cells will be collected by gentle scraping surface of the skin. Then, a superficial shave biopsy specimen, obtained by using a dermablade (a flexible, one piece blade specifically designed for shave biopsy and excision of skin lesions) will be obtained.
Study: NCT04366258

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Photobiomodulator
Description: Delivers laser-generated Near-Infrared Radiation (NIR) to forehead at 3 doses of irradiance - High (770 mW/cm2), Middle (300 mW/cm2), and Low (50 mW/cm2).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham
Description: Transcranial Photobiomodulator delivers sham irradiance dose of 0 mW/cm2.
Study: NCT02145039

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: TBI 200cGy on day -1 before transplant.
Study: NCT01828164

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: The Aevo System™ is an ultrasound emitting dental device.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham comparator
Description: Ultrasound not activated in the comparator side of the device.20 minutes per day of ultrasound treatment on the active side of the device. The device consists of a mouth guard type device with transducers embedded in the mouth guard. In the split mouth design, the treatment arm consist of the side of the mouth with the transducers activated while the comparator arm has the transducers deactivated.
Study: NCT02145039

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Haploidentical stem cell transplant
Description: Non-T-cell depleted bone marrow infusion
Study: NCT01926834

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: normal saline, 500ml,i.v.,qd, for 7 days
Study: NCT04415814

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Unilateral Pedicle Screw Fixation
Description: Pedicle screws are installed unilaterally on the one side of the vertebrae and fixed with rod

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral Pedicle Screw Fixation
Description: Pedicle screws are installed bilaterally on the both sides of the vertebrae and fixed with rods
Study: NCT02064452

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Triple P Online System
Description: The Triple P Online System (TPOS) is an online parenting support program designed to assist parents in developing effective parenting practices for handling their children's problem behaviors. Content focuses on positive attention and praise, teaching strategies, effective discipline, antecedent strategies to avoid problems in high-risk situations, and applying these principles to specific situations. TPOS integrates 3 different levels of program intensity to meet different levels of family need, based on severity of children's behavior problems.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Enhanced Usual Community Care-Waitlist
Study: NCT03635749

Intervention type: DRUG
Group type: OTHER
Intervention: Intensive antiplatelet
Description: Day 1：clopidogrel 300mg/day+ aspirin100-300mg/ day~Day2 - 21: clopidogrel 75mg/day+ aspirin 100mg/day~Day22 - 90: clopidogrel 75mg/day+aspirin placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intensive antiplatelet
Description: Day 1：clopidogrel 300mg/day+ aspirin100-300mg/ day~Day2 - 21: clopidogrel 75mg/day+ aspirin 100mg/day~Day22 - 90: clopidogrel 75mg/day+aspirin placebo
Study: NCT00495950

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaires relating to symptoms experienced during and following standard cancer treatment.
Study: NCT02401217

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phase 1- Arm 1 Infant Formula
Description: Powder infant formula

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Phase 2- Arm 2 Infant Formula
Description: Powder infant formula

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phase 2- Arm 3 Infant Formula
Description: Powder infant formula
Study: NCT00925795

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: consumption 1. EVOO; 2. ROO
Description: EVOO in doses of 50 mL/daily for 20 days; 14 days of wash-out period without olives and olive oil; followed by ROO in doses of 50 mL/daily for 20 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: consumption 1. ROO; 2. EVOO
Description: ROO in doses of 50 mL/daily for 20 days; 14 days of wash-out period without olives and olive oil; followed by EVOO in doses of 50 mL/daily for 20 days
Study: NCT03940898

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation
Description: There are two types of stimulation equipment, one is the transcranial magnetic stimulator model Magpro X100 produced by Danish Medtronic, and the other is the CCY-I TMS stimulator produced by Wuhan Eride, model B9076. The stimulating magnetic head uses an 8 shaped coil, and the stimulation site is the cerebellar vermis (ie, 1 cm below the occipital bulge), and the stimulation intensity is 100% of the motor threshold.The base frequency of the iTBS mode is 5 Hz, and one short burst stimulus occurs every 200 milliseconds. In each short array, three single pulses with a frequency of 50 Hz are buried, and each 10 short burst stimulation intervals are 8 seconds, for a total of 200 short burst stimulations. The total number of stimulation pulses is 600 per day.It takes 3 minutes and 20 seconds to complete one intervention. All participants were intervened once a day for 5 times a week for 2 weeks for a total of 10 times.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation
Description: There are two types of stimulation equipment, one is the transcranial magnetic stimulator model Magpro X100 produced by Danish Medtronic, and the other is the CCY-I TMS stimulator produced by Wuhan Eride, model B9076. The stimulating magnetic head uses an 8 shaped coil, and the stimulation site is the cerebellar vermis (ie, 1 cm below the occipital bulge), and the stimulation intensity is 100% of the motor threshold.The base frequency of the iTBS mode is 5 Hz, and one short burst stimulus occurs every 200 milliseconds. In each short array, three single pulses with a frequency of 50 Hz are buried, and each 10 short burst stimulation intervals are 8 seconds, for a total of 200 short burst stimulations. The total number of stimulation pulses is 600 per day.It takes 3 minutes and 20 seconds to complete one intervention. All participants were intervened once a day for 5 times a week for 2 weeks for a total of 10 times.
Study: NCT01564680

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: IV paracetamol infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lornoxicam
Description: 16 mg at skin closure and 8 mg 12 hours postoperative
Study: NCT03079648

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Angelica gigas N. extract
Description: capsules (2cap/d, 1,000mg/d) for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 12 weeks
Study: NCT03373825

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Take home rapid drug test
Description: The Rapid Response fentanyl test strips will be offered as take-home rapid drug tests to all participants to assess the willingness to use take-home rapid drug tests and the feasibility of using such an intervention at home. Arm 1 will be offered one method of using the take-home rapid drug test (urine testing). Arm 2 will be offered a second method of using the take-home rapid drug test (testing drug residue).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Take home rapid drug test
Description: The Rapid Response fentanyl test strips will be offered as take-home rapid drug tests to all participants to assess the willingness to use take-home rapid drug tests and the feasibility of using such an intervention at home. Arm 1 will be offered one method of using the take-home rapid drug test (urine testing). Arm 2 will be offered a second method of using the take-home rapid drug test (testing drug residue).
Study: NCT02861404

Intervention type: GENETIC
Intervention: skin flakes collection
Description: viral status assessment of skin flakes

Intervention type: GENETIC
Intervention: skin flakes collection
Description: viral status assessment of skin flakes

Intervention type: GENETIC
Intervention: skin flakes collection
Description: viral status assessment of skin flakes

Intervention type: GENETIC
Intervention: skin flakes collection
Description: viral status assessment of skin flakes

Intervention type: GENETIC
Intervention: skin flakes collection
Description: viral status assessment of skin flakes
Study: NCT01753570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFN beta(48 weeks)
Description: IFN beta: 600 MIU/day,6 days/week for initial 4 weeks following to 3 days/week for 48 weeks
Study: NCT01226160

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Postoperative face-down posturing
Description: Postoperative face-down posturing for 10 days after surgery.
Study: NCT01056458

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: auricular acupressure
Description: use the tape of ear adhesive beads on shenmen and subcortical area of both ears after three meals and before bed for three minutes each area with alternating ears, twice a week to replace paste.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham acupressure
Description: use only tape without ear adhesive beads under the same ways
Study: NCT00186875

Intervention type: DRUG
Group type: OTHER
Intervention: Etoposide, cytarabine, vincristine, dexamethasone
Description: See Detailed Description section for details of treatment interventions.

Intervention type: DRUG
Group type: OTHER
Intervention: methotrexate, teniposide, PEG-asparaginase
Description: See Detailed Description section for details of treatment interventions.

Intervention type: DRUG
Group type: OTHER
Intervention: mitoxantrone, cyclophosphamide, mercaptopurine, vinblastine
Description: See Detailed Description section for details of treatment interventions.

Intervention type: DRUG
Group type: OTHER
Intervention: L-asparaginase, erwinia asparaginase
Description: See Detailed Description section for details of treatment interventions.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: chemotherapy, intrathecal chemotherapy, steroid therapy
Description: See Detailed Description section for details of treatment interventions.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Hematopoietic Stem Cell Transplant
Description: See Detailed Description section for details of treatment interventions.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Natural Killer (NK) Cell Transplant
Description: See Detailed Description section for details of treatment interventions.
Study: NCT00750373

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Valve surgery with removal of vegetations
Description: Early valve repair or replacement with removal of vegetations within 48 hours of randomization
Study: NCT04335760

Intervention type: COMBINATION_PRODUCT
Intervention: Modified Bruce protocol on treadmill
Description: Fear of activity scale in CAD (FactCAD) was used to assess fear of activity and exercise in subjects with CAD. FactCAD is a novel scale developed specifically for patients with heart disease. Mean time to complete this self-administered scale is 4-7 minutes. The final score of the questionnaire ranges between 0 and 84. High scores indicate higher levels of fear regarding activity or exercise.~Functional capacity was assessed by 6MWT and exercise test. The 6MWT was performed to all participants according to the American Thoracic Society guidelines in a 30-m corridor10. The subjects were asked to walk as long distance as they could within 6 minutes. The 6MWT distance was recorded in meters.~Exercise test was performed using modified Bruce protocol on treadmill in institutions where technical equipment and experience was available.

Intervention type: COMBINATION_PRODUCT
Intervention: Modified Bruce protocol on treadmill
Description: Fear of activity scale in CAD (FactCAD) was used to assess fear of activity and exercise in subjects with CAD. FactCAD is a novel scale developed specifically for patients with heart disease. Mean time to complete this self-administered scale is 4-7 minutes. The final score of the questionnaire ranges between 0 and 84. High scores indicate higher levels of fear regarding activity or exercise.~Functional capacity was assessed by 6MWT and exercise test. The 6MWT was performed to all participants according to the American Thoracic Society guidelines in a 30-m corridor10. The subjects were asked to walk as long distance as they could within 6 minutes. The 6MWT distance was recorded in meters.~Exercise test was performed using modified Bruce protocol on treadmill in institutions where technical equipment and experience was available.
Study: NCT01723371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Carvedilol will be administered orally. The initial dose of carvedilol will be 0.05mg/kg/day divided into 2 doses. After two weeks, at subsequent weekly study visits, the dose of carvedilol will be increased incrementally to 0.1mg/kg in Week 2, 0.2mg/kg in Week 3, 0.4mg/kg in Week 4, 0.6mg/kg in Week 5, and 0.8mg/kg in Week 6, when the target dose of 0.8mg/kg/day (if weight is less than 62.5kg) or 50mg/day (if weight is greater than 62.5kg) is achieved. This dosage, assuming no adverse effects, will be maintained between Weeks 6 and 30 of the study. After the maintenance period from Week 6 to 30, patients will be weaned over 5 to 7 days or continued on a non-study drug supply.
Study: NCT01664260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: 0 - 8 week: 10 mg escitalopram a day + 1200 mg N-acetylcysteine twice a day
Study: NCT03635749

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard antiplatelet
Description: Day 1: Aspirin 100-300mg/day + clopidogrel placebo~Day 2 - 90: Aspirin 100mg/day+ clopidogrel placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Standard antiplatelet
Description: Day 1: Aspirin 100-300mg/day + clopidogrel placebo~Day 2 - 90: Aspirin 100mg/day+ clopidogrel placebo
Study: NCT01664260

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 - 8 week: 10 mg escitalopram a day + 1200 mg Placebo twice a day
Study: NCT03495167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SyB C-1101
Description: SyB C-1101 (rigosertib sodium) will be administered to two cohorts of patients; each receives either twice daily (560 mg before breakfast and 560 mg before dinner) or twice daily (840 mg before breakfast and 280 mg before dinner. SyB C-1101 will be administered orally twice daily for 21 consecutive days, followed by a 7-day observation period. The treatment period of 28 days (21 days of administration + 7 days of observation) constitutes 1 cycle.
Study: NCT02016027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carica folia
Study: NCT02395393

Intervention type: DEVICE
Group type: OTHER
Intervention: Alveoflex Confocal MiniprobeTM
Description: -Alveolar imaging
Study: NCT01226160

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative non-posturing group
Description: avoid a face-up position only for 10 days after surgery
Study: NCT00954759

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chiropractic treatment

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Visit without active treatment
Description: The child is brought in for chiropractic treatment, but no active treatment is delivered. The parents are unaware whether treatment is delivered or not.
Study: NCT03727074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU Cream
Description: topical cream twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efudex®
Description: topical cream twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: topical cream twice a day